Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25322872
DOI
10.1093/carcin/bgu212
PII: bgu212
Knihovny.cz E-resources
- MeSH
- Algorithms MeSH
- DNA Modification Methylases genetics MeSH
- DNA Repair Enzymes genetics MeSH
- Glioblastoma genetics mortality pathology MeSH
- Humans MeSH
- DNA Methylation MeSH
- MicroRNAs genetics MeSH
- Survival Rate MeSH
- Brain metabolism MeSH
- Biomarkers, Tumor genetics MeSH
- Tumor Suppressor Proteins genetics MeSH
- Brain Neoplasms genetics mortality pathology MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Cell Proliferation * MeSH
- Promoter Regions, Genetic genetics MeSH
- Retrospective Studies MeSH
- Neoplasm Staging MeSH
- Gene Expression Profiling * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- DNA Modification Methylases MeSH
- DNA Repair Enzymes MeSH
- MGMT protein, human MeSH Browser
- MicroRNAs MeSH
- Biomarkers, Tumor MeSH
- Tumor Suppressor Proteins MeSH
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. The prognosis of GBM patients varies considerably and the histopathological examination is not sufficient for individual risk estimation. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and were repeatedly proved to play important roles in pathogenesis of GBM. In our study, we performed global miRNA expression profiling of 58 glioblastoma tissue samples obtained during surgical resections and 10 non-tumor brain tissues. The subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples. Correlation with clinical data led to identification of six-miRNA signature significantly associated with progression free survival [hazard ratio (HR) 1.98, 95% confidence interval (CI) 1.33-2.94, P < 0.001] and overa+ll survival (HR 2.86, 95% CI 1.91-4.29, P < 0.001). O(6)-methylguanine-DNA methyltransferase methylation status was evaluated as reference method and Risk Score based on six-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients. Multivariate Cox analysis indicated that the Risk Score based on six-miRNA signature is an independent prognostic classifier of GBM patients. We suggest that the Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients.
References provided by Crossref.org
